Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. develops clinical-stage biotechnology programs for hematologic diseases, led by burixafor (GPC-100), a highly selective small-molecule CXCR4 antagonist. Company updates center on burixafor's role in hematopoietic stem cell mobilization for multiple myeloma transplant settings, sickle cell disease, cell and gene therapy support, and acute myeloid leukemia chemosensitization.
Recurring news also covers clinical data presentations and publications, collaborations for combination approaches, financial results, liquidity disclosures, and research spending following Exicure's acquisition of GPCR Therapeutics USA. Earlier company context includes its historical focus on nucleic acid therapies and restructuring before the current hematology-focused pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exicure, Inc. (NASDAQ: XCUR) has appointed Jung-Sang (Michael) Kim as the new CEO and CFO, effective April 26, 2023. He takes over from Dr. Matthias Schroff and Elias D. Papadimas, who both stepped down on the same day. The Board also welcomed Jiyoung Hwang as a new Class I director and noted the resignation of Seung Soo Shin as Class II director and chairman. Exicure is an early-stage biotechnology firm focusing on nucleic acid therapies for RNA targeting. Following a restructuring and the suspension of clinical activities, the company is exploring strategic alternatives to enhance stockholder value. For more details, a comprehensive filing will be available on Form 8-K with the U.S. Securities and Exchange Commission.
Exicure, Inc. (Nasdaq: XCUR) reported financial results for 2022, highlighting a revenue increase to $28.8 million from $(0.5) million in 2021 due to the recognition of deferred revenue from terminated collaborations. The company has $9.8 million in cash and expects to need additional financing soon. R&D expenses decreased 60% to $19.8 million, partly due to a reduction in workforce. The net loss improved to $2.6 million from $64.1 million. Despite these changes, Exicure faces substantial doubt about its ability to continue as a going concern without new financing.